Bo-Ching Lee1, Kao-Lang Liu1, Cheng-Li Lin2,3, Chia-Hung Kao4,5,6. 1. Department of Medical Imaging, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 2. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. 3. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 4. Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung, 40447, Taiwan, Republic of China. d10040@mail.cmuh.org.tw. 5. Department of Nuclear Medicine and PET Centre, China Medical University Hospital, Taichung, Taiwan. d10040@mail.cmuh.org.tw. 6. Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan. d10040@mail.cmuh.org.tw.
Abstract
OBJECTIVE: This nationwide population-based cohort study evaluated the association between acute kidney injury (AKI) and transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). METHODS: The case cohort included patients with HCC who had undergone TACE treatment between 1 January 1998 and 31 March 2010. Patients with baseline chronic kidney disease, with baseline end-stage renal disease, and aged younger than 20 years were excluded. HCC patients with TACE and HCC patients without TACE were matched 1:1 in terms of propensity scores. RESULTS: A total of 1132 HCC patients with TACE and 1132 HCC patients without TACE (controls) were enrolled, of which 72 and 66 patients developed AKI, respectively. After adjustment for age, sex, comorbidity, and other medications, the risk of AKI was higher in HCC patients with TACE [hazard ratio (HR) = 1.66, 95% CI = 1.17-2.34]. The HRs of post-TACE AKI were 1.56 (95% CI = 1.02-2.37) and 1.74 (95% CI = 1.23-2.48) for patients having at least one comorbidity and less frequent sessions of TACE (≤3 times), respectively. CONCLUSIONS: Our study demonstrates that TACE increases the risk of AKI in patients with HCC without chronic kidney disease or end-stage renal disease. KEY POINTS: • Seventy-two of1132 patients with TACE and 62/1132 patients without TACE developed AKI. • AKI risk was higher in HCC patients with TACE. • HRs were 1.56 and 1.74 for those with comorbidities and less frequent TACE.
OBJECTIVE: This nationwide population-based cohort study evaluated the association between acute kidney injury (AKI) and transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). METHODS: The case cohort included patients with HCC who had undergone TACE treatment between 1 January 1998 and 31 March 2010. Patients with baseline chronic kidney disease, with baseline end-stage renal disease, and aged younger than 20 years were excluded. HCC patients with TACE and HCC patients without TACE were matched 1:1 in terms of propensity scores. RESULTS: A total of 1132 HCC patients with TACE and 1132 HCC patients without TACE (controls) were enrolled, of which 72 and 66 patients developed AKI, respectively. After adjustment for age, sex, comorbidity, and other medications, the risk of AKI was higher in HCC patients with TACE [hazard ratio (HR) = 1.66, 95% CI = 1.17-2.34]. The HRs of post-TACE AKI were 1.56 (95% CI = 1.02-2.37) and 1.74 (95% CI = 1.23-2.48) for patients having at least one comorbidity and less frequent sessions of TACE (≤3 times), respectively. CONCLUSIONS: Our study demonstrates that TACE increases the risk of AKI in patients with HCC without chronic kidney disease or end-stage renal disease. KEY POINTS: • Seventy-two of1132 patients with TACE and 62/1132 patients without TACE developed AKI. • AKI risk was higher in HCC patients with TACE. • HRs were 1.56 and 1.74 for those with comorbidities and less frequent TACE.
Authors: Thomas J Vogl; Johannes Lammer; Riccardo Lencioni; Katerina Malagari; Anthony Watkinson; Frank Pilleul; Alban Denys; Clara Lee Journal: AJR Am J Roentgenol Date: 2011-10 Impact factor: 3.959
Authors: Sushrut S Waikar; Ron Wald; Glenn M Chertow; Gary C Curhan; Wolfgang C Winkelmayer; Orfeas Liangos; Marie-Anne Sosa; Bertrand L Jaber Journal: J Am Soc Nephrol Date: 2006-04-26 Impact factor: 10.121
Authors: G F Stefanini; P Amorati; M Biselli; F Mucci; A Celi; V Arienti; R Roversi; C Rossi; G Re; G Gasbarrini Journal: Cancer Date: 1995-05-15 Impact factor: 6.860
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Won Sohn; Cheol Bae Ham; Nam Hee Kim; Hong Joo Kim; Yong Kyun Cho; Woo Kyu Jeon; Byung Ik Kim Journal: PLoS One Date: 2020-12-14 Impact factor: 3.240
Authors: Deok-Gie Kim; Shin Hwang; Jong Man Kim; Je Ho Ryu; Young Kyoung You; Donglak Choi; Bong-Wan Kim; Dong-Sik Kim; Yang Won Nah; Tae-Seok Kim; Jai Young Cho; Geun Hong; Jae Do Yang; Jaryung Han; Suk-Won Suh; Kwan Woo Kim; Yun Kyung Jung; Ju Ik Moon; Jun Young Lee; Sung Hwa Kim; Jae Geun Lee; Myoung Soo Kim; Kwang-Woong Lee; Dong Jin Joo Journal: J Clin Med Date: 2022-07-20 Impact factor: 4.964